Psychomotor Effect of VI-0521 in Healthy Overweight and Obese Subjects

Phase 2, randomised, double-blind trial of phentermine + topiramate in obesity and Overweight (4 arms), sponsored by VIVUS. Primary endpoints: Measure of Psychomotor Function Using Speed and Coordination on the CogScreen Pathfinder Number (PFN) Test in Subjects Treated With Alcohol Compared to Alcohol Placebo in Period 1 and Measure of Psychomotor Function Using Speed and Coordination on the CogScreen Pathfinder Number (PFN) Test in Subjects Treated With VI-0521 Compared to Placebo in Periods 2 and 3. Started Dec 2008; status: completed.